Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial

Neurology

Volumn 65, Issue 2, 2005, Pages 286-292

  Puri, B K ^a   Leavitt, B R ^b   Hayden, M R ^b   Ross, C A ^c   Rosenblatt, A ^c   Greenamyre, J T ^d   Hersch, S ^e   Vaddadi, K S ^f   Sword, A ^g   Horrobin, D F ^h   Manku, M ^h   Murck, Harald ^h  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MONASH UNIVERSITY   (Australia)

^g Centum   (United Kingdom)

^h Amarin Neuroscience Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ICOSAPENTAENOIC ACID ETHYL ESTER; LAX 101; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BEHAVIOR; CHI SQUARE TEST; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NUCLEOTIDE REPEAT; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 22544452137     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000169025.09670.6d     Document Type: Article

References (34)

1. Siemers E, Huntington disease. Arch Neurol 2001;58:308-310.
2. Koroshetz WJ. Huntington's disease. In: Office practice of neurology, Samuels MA, Feske S, eds. New York: Churchill Livingstone, 1996:654-661.
3. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-1210.
4. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
5. Kirkwood SC, Su JL, Conneally PM, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001;58:273-278.
6. Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002;5:731-736.
7. Sawa A. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria? J Mol Med 2001;79:375-381.
8. Sawa A, Wiegand GW, Cooper J, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999;5:1194-1198.
9. Liu YF. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 1998;273:28873-28877.
10. Merienne K, Helmlinger D, Perkin GR, Devys D, Trottier Y. Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J Biol Chem 2003;278:16957-16967.
11. Hughes RE, Olson JM. Therapeutic opportunities in polyglutamine disease. Nat Med 2001;7:419-423.
12. McMurray CT. Huntington's disease: new hope for therapeutics. Trends Neurosci 2001;24:S32-S38.
13. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004;5:373-384.
14. Verbesssem P, Hespel P, Dom R. Oral creatine supplementation in patients with Huntington's disease. Neurology 2002;58(suppl 3):A334. (Abstract).
15. Kieburtz K. The Huntington's Study Group. Placebo-controlled trial of creatine in Huntington's disease. Neurology 2001;56:S49.004. Abstract.
16. Huntington Study Group. A randomized, placebo-controlled trial of co-enzyme Q(10) and remacemide in Huntington's disease. Neurology 2001;57:397-404.
17. Froyland L, Madsen L, Vaagenes H, et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 1997;38:1851-1858.
18. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755-8758.
19. Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. J Biol Chem 2002;277:20804-20811.
20. Martin DSD, Lonergan PE, Boland B, et al. Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. J Biol Chem 2002;277:34239-34246.
21. Vaddadi K. Essential fatty acids and movement disorders. In: Phospholipid spectrum disorder in psychiatry. Peet M, Glen I, Horrobin DF, eds. Carnforth, UK: Marius Press, 1999:285-296.
22. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002;13:29-33.
23. Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002;13:123-126.
24. Hattori Y, Matsuda M, Eizawa T, Nakajima K. [A case of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), showing temporary improvement during the treatment with eicosapentaenoic acid ethyl ester]. Rinsho Shinkeigaku 2001;41:668-672.
25. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142.
26. Helder DI, Kaptein AA, van Kempen GMJ, van Houwelingen JC, Roos RAC. Impact of Huntington's disease on quality of life. Mov Disord 2001;16:325-330.
27. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998;13:915-919.
28. Siesling S, Zwinderman AH, van Vugt JP, Kieburtz K, Roos RA. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. Mov Disord 1997;12:229-234.
29. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171-179.
30. Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med 1995;14:1913-1925.
31. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation. Biometrika 1999;86:948-955.
32. Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61: 1085-1092.
33. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-919.
34. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-479.